(Q44829697)

6 December 2017

title

The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers (English)

1 reference

6 December 2017

1 reference

ChEBI release 2020-05-28

1 reference

Johan Areberg

1

1 reference

6 December 2017

Birgitte Søgaard

series ordinal

2

1 reference

6 December 2017

Astrid-Maria Højer

series ordinal

3

1 reference

6 December 2017

publication date

24 April 2012

1 reference

Basic and Clinical Pharmacology and Toxicology

6 December 2017

published in

1 reference

6 December 2017

volume

111

1 reference

6 December 2017

issue

3

1 reference

6 December 2017

page(s)

198-205

1 reference

Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00886.X

Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00886.X

Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00886.X

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2012.00886.X

10.1111/J.1742-7843.2012.00886.X

21 January 2018

Identifiers

DOI

1 reference

release_ynijudqjtnd3tktwzzo4kccr3u

6 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ynijudqjtnd3tktwzzo4kccr3u

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference